Anthony El-Khoueiry
@DrElkhoueiry
ID:1727505096
04-09-2013 04:13:04
174 Tweets
606 Followers
231 Following
Anthony El-Khoueiry on 4-yr OS of STRIDE in #HCC and value of priming dose of anti-CTLA4, emerging #1L #IO /VEGF & into earlier #HCC settings ( #EMERALD ), novel #IO -based & targeted tx’s in #biliarytractccancer
5th Annual Cedars-Sinai #GI Tumor Conf cedars.cloud-cme.com/course/courseo…
OncoAlert
Important discussion on hepatobiliary cancer: the new frontiers of immunotherapy in hepatocellular carcinoma and emerging actionable targets in biliary tract cancers with Anthony El-Khoueiry, Dr. Diana L Hanna and John Marshall at #SOGO . USC Norris Comprehensive Cancer Center Keck Medicine of USC PER
Please join Dr. Andrew Hendifar Arsen Osipov, MD & us at Cedars-Sinai 5th Annual #GI Tumor Conf w/a stellar #KOL line-up of speakers in #oncology Dr. Marwan G. Fakih Dr. Randy Hecht, Dr. Philip Philip, Dr. Ed Wolin Anthony El-Khoueiry Tatiana Prowell, MD
3/23/24 hybrid event
Register at:
cedars.cloud-cme.com/course/courseo…
Anjana Pillai launching our annual HCC-Live meeting with the “Year in Review”; amazing fact that advances in HCC continue to happen on a yearly basis! HCC-LIVE Conference Amit G Singal Julie Heimbach Riad Salem Anjana Pillai
HCC-LIVE Conference is about to start!
The one persistent comment I heard from attendees at yesterday’s opening reception is:
“IT’S MY FAVORITE MEETING OF THE YEAR”
congrats to Anjana Pillai Amit G Singal Anthony El-Khoueiry Riad Salem Julie Heimbach #LiverTwitter
Team bonding at Stand Up to Cancer Scientific Summit 2024! Our USC Norris Comprehensive Cancer Center team presented an update on our SU2C funded projects to increase diversity in early phase trials! Thank you SU2C for a great meeting! SU2Cscience USC Norris Comprehensive Cancer Center Chanita Halbert
T-13 days for HCC-LIVE Conference . Registration is filling up fast!! Come join us for great discussions, heated debates, up to date treatment paradigms and the donut wall 🍩 Amit G Singal Anthony El-Khoueiry Riad Salem Julie Heimbach
Join our outstanding Mayo Clinic Comprehensive Cancer Center and guest faculty on Nov 10-11 in Las Vegas (or via livestream) for 2023 Mayo Clinic #livercancer #pancreascancer #cholangiocarcinoma Symposium! Registration information and the program schedule are available here: tinyurl.com/mvjeuc3w
Course Directors invite the submission of abstracts regarding advances in therapeutics, diagnosis, pathogenesis, and management of hepatocellular carcinoma. Deadline: December 15, 2023.
hcc-live.org/call-for-abstr…
#HCC LIVE #HCC Julie Heimbach Anthony El-Khoueiry Anjana Pillai Amit G Singal
Looking forward to a great discussion on liver cancer with Katie Kelley, Anthony El-Khoueiry and Neil Love
Research to Practice
Breakfast with the investigators “hepatobiliäry Cancers”
ESMO - Eur. Oncology EASL Education ILCA OncoAlert #livertwitter
Anthony El-Khoueiry, MD, and Chanita Hughes-Halbert, PhD, discuss their role within the Stand Up To Cancer (Stand Up To Cancer) 4-team initiative, focusing on diversity in early-phase clinical trials. Anthony El-Khoueiry @Chanita_Halbert OncLive.com
onclive.com/view/drs-el-kh…
We are excited to announce that USC Norris is collaborating with Auransa Inc. on a phase 1 clinical trial to evaluate a new kind of treatment for cancers of the liver and solid tumors with liver dominant disease. Learn more here:
uscnorriscancer.usc.edu/2023/03/23/usc…
#livercancer
Honored to lead one of four teams funded by SU2C to increase diversity in early phase clinical trials. Looking forward to working with my co-leader Chanita Halbert and an amazing group of colleagues USC Norris Comprehensive Cancer Center Jorge Nieva Jennifer Tsui Anastasia Martynova, MD bit.ly/3lfoIjb
So glad to have this great line up of GI oncologists at the Mayo Clinic Clinical Multidisciplinary Hematology and Oncology 18th Annual Review! Anthony El-Khoueiry Joleen Hubbard Jeremy Jones Daniel Ahn Bassam Sonbol
WOW! Anthony El-Khoueiry presents BOTENSILMAB and survival in patients with MSS CRC! #GI23 ASCO Agenus Inc. ($AGEN) MiNK Therapeutics
IMbrave151 phase 2 study of gem/cis/atezo/bev vs. gem/cis/atezo/placebo in advanced #biliarycancer ➡️ improved PFS with bev HR 0.76, same ORR ~24%, possible OS benefit Anthony El-Khoueiry $GENE
#GI23 ASCO Cure GI Cancers OncoAlert